October 8, 2023 from 12:00 pm – 1:15 pm HST
Supported By: an educational grant from AstraZeneca Pharmaceuticals.
Program Description
The discovery of the mechanisms of type 2 (T2) inflammation in asthma gave rise to biologic therapies that have dramatically expanded treatment options for patients with moderate-to-severe eosinophilic or allergic asthma. Newly approved and emerging therapies that target the epithelial alarmins represent an important opportunity to improve outcomes for patients with a broad range of asthma phenotypes. In this CME satellite symposium, presented by National Jewish Health, expert faculty will provide insights into the new paradigm of treatments and how to manage the complexity of severe asthma treatment.
This program will focus the role of epithelial alarmins in the inflammatory cascade of asthma, and connecting clinical characteristics and patient subtypes to treatment targets. Topics include: current challenges in severe asthma management; the pathophysiology of severe asthma targets for current and emerging treatments; and selecting treatments based on patient phenotypes.
At the completion of the activity, attendees will be able to:
- Explain the mechanisms of action of biologic therapies for severe asthma and key features of severe asthma that are targets for treatment.
- Describe the role of the respiratory epithelium in asthma and the relationship to T2 and non-T2 airway inflammation.
- Evaluate the emerging data for new and emerging therapies that target the epithelial alarmins.
- Connect clinical characteristics and phenotypes to the targeted treatment.
Accreditation and Designation Statements:
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
National Jewish Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.
Speakers
Eileen Wang, MD, MPH
National Jewish Health
Division of Allergy & Clinical Immunology
Assistant Professor
Denver, CO
Rohit K. Katial, MD
National Jewish Health
Division of Allergy & Clinical Immunology
Professor of Medicine
Denver, CO
Michael E. Wechsler, MD, MMSc
National Jewish Health
The Cohen Family Asthma Institute
Director
National Jewish Health
Division of Pulmonary, Critical Care, & Sleep Medicine
Professor of Medicine
Denver, CO